Yahoo Finance

UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also views Novo’s updates a positive read-through to Amgen, saying CagriSema’s efficacy now seems mostly in-line with MariTide, with likely gastrointestinal intolerability issues, and could appear less attractive with MariTide being a monthly titration regimen.

Don't Miss Our Christmas Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on LLY:

• Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

• Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA

• End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink

• Hims & Hers falls after FDA ends shortage of Lilly weight loss drug

• Trump’s Key Advisors Are Split on Whether Medicare Should Cover Weight-Loss Drugs